NasdaqCM:MDXGBiotechs
MiMedx (MDXG): Fresh Clinical Evidence Spurs a Closer Look at the Stock’s Valuation and Long-Term Upside Potential
MiMedx Group (MDXG) just added fresh peer reviewed backing for its placental allograft products, with a new Journal of Inflammation study underscoring their immunomodulatory role in complex wound healing and longer term competitive positioning.
See our latest analysis for MiMedx Group.
Even with this new clinical validation, MiMedx Group’s $7.05 share price sits well below its highs, with a year-to-date share price return of negative 24.03 percent and a powerful three-year total shareholder...